AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

by Barry101 | Feb 18, 2020 | Press Release, Uncategorized

OCALA, FL / February 18, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update...

AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus

by Barry101 | Feb 12, 2020 | Press Release, Uncategorized

OCALA, FL / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive...

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

by Barry101 | Feb 11, 2020 | Press Release, Uncategorized

Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed broad-spectrum ‘universal’ coronavirus vaccine OCALA, FL / February 11, 2020 / AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies

by Barry101 | Feb 5, 2020 | Press Release, Uncategorized

OCALA, FL / February 5, 2020 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced posting by the University of Pittsburgh Medical Center (UPMC)...

AIM ImmunoTech to Present at the Investor Summit in Philadelphia

by Barry101 | Dec 11, 2019 | Press Release, Uncategorized

OCALA, FL / December 11, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced that it will be presenting at the Investor Summit being held...

AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

by Barry101 | Dec 4, 2019 | Press Release, Uncategorized

OCALA, FL / December 4, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as severe chronic fatigue syndrome (CFS)...